Clinical differentiation of low molecular weight heparins

Seminars in Thrombosis and Hemostasis

Volumn 25, Issue SUPPL. 3, 1999, Pages 135-144

  Mammen, Eberhard F ^a   Arcelus, Juan ^a   Messmore, Harry ^a   Raul, Altman ^a   Nurmohamed, Michael ^a   Eldor, Amiram ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; TINZAPARIN;

ARTERY THROMBOSIS; CONFERENCE PAPER; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; GENERAL SURGERY; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HUMAN; ORTHOPEDIC SURGERY; PRIORITY JOURNAL; THROMBOSIS; TREATMENT INDICATION;

CORONARY DISEASE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; VENOUS THROMBOSIS;

EID: 0032750368     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Fareed J, Jeske W, Hoppensteadt D, Clarizio R, Walenga JM. Are the available low molecular weight heparin preparations the same? Semin Thromb Hemost 1996;22(Suppl 1):77-91
2. Fareed J, Walenga JM, Hoppensteadt D, et al. Biochemical and pharmacological inequivalence of low molecular weight heparins. Ann N Y Acad Sei 1989:556:333-353
3. Fareed J, Jeske W, Hoppensteadt D, Clarizio R, Walenga JM. Low molecular weight heparins: Pharmacologie' profile and product differentiation. Am J Cardiol 1998;82:3L-10L
4. Barrowcliffe TW. Annotation: Low molecular weight heparins. BrJHaematol 1995;90:1
5. Hirsh J. Low molecular weight heparin for the treatment of venous thromboembolism. Am Heart J 1998;135:S336-S342
6. Amman EM, Handin R. Low molecular weight heparins: An intriguing new twist with profound implications. Circulation 1998;98:287-289
7. Montalescot G, Philippe F, Annick A, et al. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease. Beneficial effects of enoxaparin. Circulation 1998;98:294-299
8. Kleber FX, Wilt C, Flosbach CW, and the PRINCE Study Group. Study to compare the efficacy and safety of the LMWH enoxaparin and standard heparin in the prevention of thromboembolic events in medical patients with cardiopulmonary diseases. Ann Hematol 1998;76 Suppl. I: Abstract P269
9. Bianchini P, Bergonzini GL, Parma B, Osima B. Relationship between plasma antifactor Xa activity and the antithrombotic ac-tivity of heparins of different molecular mass. Haemostasis 1995;25:288-298
10. Ockelford P, Carter CJ, Mitchell L, Hirsh J. Discordance between the anti-Xa activity and the antithrombotic activity of an ultra low molecular weight heparin fraction. Thromb Res 1982;28: 401-409
11. Hoppenstaedt D, Walenga JM, Fareed J. Relevance of laboratory parameters to the clinical efficacy of Fraxiparin©. Thromb Haemorrh Disord 1991;4:7-12
12. Troy S, Fruncillo R, Ozawa T, et al. Absolute and comparative subcutaneous bioavailability of ardeparin sodium, a low molecular weight heparin. Thromb Haemost I997;78:871-875
13. Fareed J. Current trends in antithrombotic drug and device development. Semin Thromb Hemost 1996;22:3-8
14. Ozawa T, Mammen EF. LMW heparin (anti-Xa) assays for clinical monitoring and pharmacokinetic studies on the Automated Coagulation Laboratory (ACL). Thromb Res 1992;66:287-298
15. Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic pathway inhibitor (EPI). Thromb Res 1988;50:803-813
16. Marsh N. Annotation: Does heparin stimulate fibrinolysis? Br J Haematol 1990;76:163-167
17. Schneider DJ, Tracy PB, Mann KG, Sobel BE. Differential effects of anticoagulants on the activation of platelets ex vivo. Circulation 1997;96:2877-2883
18. Myrup B, Jensen T, Gram 3, et al. No effect of unfractionated heparin or low molecular weight heparin treatment on markers of vascular wall and hemostatic function in incipient diabetic nephropathy. Diabetes Care 1997;20:1615-1619
19. Ozawa T, Domagalski J, Mammen EF. Determination of low molecular weight heparin by Heptest® on the Automated Coagulation Laboratory (ACL) system. Am J Clin Pathol 1993; 99:157-162
20. Thromboembolic Risk Factors (THRIFT) Consensus Group. Risk of and prophylaxis for venous thromboembolism in hospital patients. Br Med J 1992;305:567-74
21. Nicolaides AN. Consensus statement: Prevention of venous thromboembolism. Int Angiol 1997;16:3-38
22. Clagett GP, Anderson FA, Heit J, Levine MN, Wheeler HB. Prevention of venous thromboembolism. Chest 1995;108:312S-334S
23. Lindahl B, Venge P, Wallentin L. Troponin-T identifies patients with unstable coronary artery disease who benefit from longterm antithrombotic protection. J Am Coll Cardiol 1997;29: 43-48
24. Toss H, Lindahl B, Siegbahn A, Wallentin L. Prognostic influence of increased fibrinogen and C-reactive protein in unstable coronary artery disease. FRISC Study Group, Fragmin during Instability in Coronary Artery Disease. Circulation 1997;96:4204-4210
25. Edmonson RA, Cohen AT, Das SK, et al. Low molecular weight heparin versus aspirin and dipyridamole after femoropopliteal bypass grafting. Lancet 1994;344:914-918
26. Fuster V, Badimon L, Cohen M, et al. Insights into the pathogenesis of acute ischémie syndromes. Circulation 1988:77:1213-1220
27. Davies MJ, Thomas A. Plaque fissuring: The cause of acute myocardial infarction, sudden ischémie death, and crescendo angina. Br Heart J 1985:53:363-373
28. Gurfinkel EP, Manos EJ, Mejail RI, et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol 1995;26: 313-318
29. Fragmin during Instability in Coronary Artery Disease (FRISC) Study Group. Low molecular weight heparin during instability in coronary artery disease. Lancet 1996:347:561-568
30. Klein W, Buchwald A, Hillis SE, et al. Comparison of low molecular weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC). Circulation 1997:96:61-68
31. Cohen M, Demers C, Gurfmkel EP, et al. A comparison of low molecular weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337:447-453
32. Suvarna TT, Parikh JA, Keshav R, et al. Comparison of clinical outcome of fixed-dose subcutaneous low molecular weight heparin (tinzaparin) with conventional heparin in unstable angina: A pilot study. Indian Heart J 1997;49:159-162
33. TheThrombolysis in Myocardial Infarction (TIMI) HATrial Investigators. Dose-ranging trial of enoxaparin for unstable angina: Results of TIMI 1 TA. J Am Coll Cardiol 1997;29:1474-1482
34. Antman EM, McCabe CH, Premmereur J, et al. Enoxaparin for the acute and chronic management of unstable angina/non-Qwave myocardial infarction. Results of TIMI 11B. Circulation 1999 (in press)
35. Leizorovicz A. PRAXIS: Fraxiparine in ischémie syndromes. Presentation at the European Society of Cardiology. Vienna, August, 1998
36. Fragmin+SK study
37. Faxon DP, Spiro TE, Minor S, et al. and the ERA investigators. Low molecular weight heparin in prevention of restenosis after angioplasty: Results of enoxaparin restenosis (ERA) trial. Circulation 1994;90:908-916
38. Cairns JA, Gill J, Morion B, et al. for the EMPAR collaborators. Fish oils and low molecular weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty: The EMPAR study. Circulation 1996;94:1553-1560
39. Karsch KR, Preisack MB, Baildon R, et al. and the REDUCE trial group. Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty: Results of a randomized, double-blind, unfractionated heparin and placebocontrolled, multicenter trial (REDUCE trial). J Am Coll Cardiol 1996;28:1437-1443
40. Zidar JP. Low molecular weight heparin in coronary stenting (the ENTICES trial). Am J Cardiol 1998;82:29L-32L
41. Lablanche JM, McFadden EP, Meneveau N, et al. Effect of nadroparin, a low molecular weight heparin, on clinical and angiographie restenosis after coronary balloon angioplasty: The FACT study. Fraxiparine Angioplastie Coronaire Transluminale. Circulation 1997;96:3395-3402.
42. Deutsch E, Kiesz SR, Martin JL, et al. Favorable impact of low molecular weight heparin delivered at the time of stent deployment on late loss in de novo lesions. Poster presentation at: The Emerging Role of Low Molecular Weight Heparins in Acute Coronary Syndromes. Satellite symposium at: 70th Scientific Session of the American Heart Association, Orlando, Florida US A 9 November 1997
43. Nightingale SL for the PDA. Appropriate use of low molecular weight heparins. JAMA 1993;270(4):1672
44. Horlocker TT, Wedel DJ. Spinal and epidural blockade and perioperative low molecular weight heparin: Smooth sailing on the Titanic. Anesth Analg 1998;86:1153-1156
45. PDA Public Health Advisory. Anesth Analg 1998;86:1156
46. Dahl OE, Andreassen G, Aspelin T, et al. Prolonged thromboprophylaxis following hip replacement surgery-results of a double-blind, prospective, randomized, placebo-controlled study with dalteparin. Thromb Haemost 1997;77:26-31
47. Bergqvist D, Benoni G, Bjorgell O, et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 1996;335:696-700
48. Dahl S, et al. The effect of prolonged thromboprophylaxis with dalteparin on the frequency of deep vein thrombosis and pulmonary embolism 35 days after hip replacement surgery. Thromb Haemost I995;73:1094(Abstr)
49. Lassen MR, et al. Prolonged thromboprophylaxis with low molecular weight heparin (fragmin) after elective total hip arthroplasty-a placebo-controlled study. Thromb Haemostas 1995:73:1104(Abstr)
50. Planes AN, Vochelle N, Darmon J-Y, et al. Risk of deep venous thrombosis after hospital discharge in patients undergoing total hip replacement. Double-blind randomized comparison of enoxaparin versus placebo. Lancet 1996;348:224-228
51. Hunt BJ, Doughty H-A, Majumdar G, et al. Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies. Thromb Haemost 1997:77:39-43
52. Dulitzki M, Pauzner R, Langevitz P, et al. Low molecular weight heparin during pregnancy and delivery: Preliminary experience with 41 pregnancies. Obstet Gynecol 1996;87:380-383
53. Nelson-Piercy C, Letsky EA, de Swiet M. Low molecular weight heparin for obstetric thromboprophylaxis: Experience of sixtynine pregnancies in sixty-one women at high risk. Am J Obstet Gynecol 1997; 176:1062-1068
54. Harenberg J, Huhle G, Piazolo L, Giese C, Heene DL. Long-term anticoagulation of outpatients with adverse events to oral anticoagulants using low molecular weight heparin. Semin Thromb Hemost 1997:23:167-172
55. Sanson BJ, Lensing RW, Prins MH, et al. Safety of low molecular weight heparin in pregnancy: A systematic review. Thromb Haemost 1999:81:668-672
56. Prandoni P. Prevention of thrombosis in patients with malignancy. Cardiovasc Risk Factor 1995:5:299-304
57. Neri Serneri GG, Gensini OF, Crmoval M, et al. Association between time of increased fibrinopeptide A levels and episodes of spontaneous angina: A controlled prospective study. Am Heart J 1987:113:672-678
58. Smith P. Long-term anticoagulant treatment after acute myocardial infarction: The Warfarin Re-Infarction Study. Ann Epidemiol 1992:2:549-552
59. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994;343:499-503
60. Cairns JA, Theroux P, Lewis HD Jr, et al. Antithrombotic agents in coronary artery disease. Chest 1998:114:611S-633S.